Details of the Drug Combination

General Information of Drug Combination (ID: DC5ROEX)

Drug Combination Name
Atorvastatin Colchicine
Indication
Disease Entry Status REF
Non ST Segment Elevation Acute Coronary Syndrome Phase 2 [1]
Component Drugs Atorvastatin   DMF28YC Colchicine   DM2POTE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Atorvastatin
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [2]
Angina pectoris BA40 Approved [2]
Arteriosclerosis BD40 Approved [2]
Cardiovascular disease BA00-BE2Z Approved [3]
Coronary atherosclerosis N.A. Approved [2]
Hypercholesterolaemia 5C80.0 Approved [2]
Hyperlipidemia 5C80.Z Approved [4]
Hyperlipidemia, familial combined, LPL related N.A. Approved [2]
Hypertriglyceridemia 5C80.1 Approved [2]
Inflammation 1A00-CA43.1 Approved [2]
Non-insulin dependent diabetes 5A11 Approved [2]
Psoriasis EA90 Approved [2]
Type-1/2 diabetes 5A10-5A11 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]
Stroke 8B20 Investigative [2]
Venous thromboembolism BD72 Investigative [2]
Atorvastatin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [13]
HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway) TTDJB68 N.A. Inhibitor [14]
------------------------------------------------------------------------------------
Atorvastatin Interacts with 7 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [15]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [16]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [17]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [18]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [19]
Monocarboxylate transporter 1 (SLC16A1) DT342ZG MOT1_HUMAN Substrate [20]
Monocarboxylate transporter 2 (SLC16A7) DTLT3UG MOT2_HUMAN Substrate [21]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTP(s)
Atorvastatin Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [22]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [23]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [24]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [25]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [26]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [27]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Atorvastatin Interacts with 93 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Increases ADR [28]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Activity [29]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Decreases Expression [30]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Increases Expression [31]
Kinesin-like protein KIF6 (KIF6) OTDH3MR4 KIF6_HUMAN Increases Response To Substance [32]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Decreases Activity [33]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Increases Expression [34]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Expression [35]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Activity [35]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Decreases Expression [30]
Sterol 26-hydroxylase, mitochondrial (CYP27A1) OT649C01 CP27A_HUMAN Decreases Expression [30]
Angiopoietin-2 (ANGPT2) OTEQK65P ANGP2_HUMAN Increases Expression [10]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Expression [10]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Decreases Expression [10]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [10]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Increases Expression [10]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases Activity [36]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [37]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Expression [38]
Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2) OTBL2W7R GTR2_HUMAN Decreases Expression [38]
Hexokinase-4 (GCK) OTR3Q0NN HXK4_HUMAN Decreases Expression [38]
Toll-like receptor 4 (TLR4) OTP7ML3S TLR4_HUMAN Increases Expression [39]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Increases Expression [39]
Prothrombin (F2) OTNFSM49 THRB_HUMAN Decreases Activity [40]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [41]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Increases Expression [31]
Insulin (INS) OTZ85PDU INS_HUMAN Increases Expression [42]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [11]
Interleukin-2 receptor subunit alpha (IL2RA) OT0MWCHG IL2RA_HUMAN Affects Expression [39]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [43]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [44]
Transferrin receptor protein 1 (TFRC) OT8ZPBDL TFR1_HUMAN Affects Expression [39]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Increases Expression [43]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Expression [45]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Expression [46]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [41]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [47]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [48]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Decreases Expression [49]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases Expression [11]
Integrin beta-1 (ITGB1) OT6G1IAR ITB1_HUMAN Increases Expression [50]
Rho-related GTP-binding protein RhoC (RHOC) OTOLE1FT RHOC_HUMAN Decreases Localization [51]
Monocyte differentiation antigen CD14 (CD14) OT83GJ47 CD14_HUMAN Decreases Expression [52]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [53]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [48]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [53]
Integrin alpha-M (ITGAM) OTAG6HWU ITAM_HUMAN Decreases Expression [52]
Coagulation factor V (F5) OTDMZ3LT FA5_HUMAN Decreases Activity [40]
Bone morphogenetic protein 2 (BMP2) OT23T37S BMP2_HUMAN Increases Expression [43]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [48]
E-selectin (SELE) OT33RZWY LYAM2_HUMAN Increases Expression [11]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) OT2D9DOV TNR1A_HUMAN Decreases Expression [49]
Integrin alpha-X (ITGAX) OTOGIMHE ITAX_HUMAN Decreases Expression [52]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [39]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [53]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [53]
Interleukin-12 subunit alpha (IL12A) OTDQT8GI IL12A_HUMAN Decreases Expression [54]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [55]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [47]
Nicotinamide N-methyltransferase (NNMT) OTFM38GU NNMT_HUMAN Increases Expression [56]
T-lymphocyte activation antigen CD86 (CD86) OTJCSBPC CD86_HUMAN Decreases Expression [39]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) OTTOMI8J PK3CA_HUMAN Decreases Expression [41]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [53]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [53]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [57]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [58]
Importin subunit alpha-1 (KPNA2) OTU7FOE6 IMA1_HUMAN Affects Localization [59]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Decreases Expression [31]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [60]
Transforming protein RhoA (RHOA) OT6YOJ9N RHOA_HUMAN Decreases Activity [53]
Rho-related GTP-binding protein RhoB (RHOB) OTHQFQF7 RHOB_HUMAN Increases Expression [51]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [46]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [41]
CD83 antigen (CD83) OT1V4WQF CD83_HUMAN Decreases Expression [39]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [61]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [53]
Peroxisome proliferator-activated receptor alpha (PPARA) OTK095PP PPARA_HUMAN Decreases Expression [62]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Increases Localization [58]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) OT7TNF0L AAPK1_HUMAN Increases Activity [56]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [60]
Serum paraoxonase/arylesterase 2 (PON2) OT55NCTD PON2_HUMAN Increases Expression [63]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Decreases Expression [42]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Expression [46]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [61]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Increases Phosphorylation [56]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Response To Substance [47]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [64]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases ADR [28]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Transport [65]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1) OTERJ4VQ SO2B1_HUMAN Increases Uptake [66]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Decreases Transport [67]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Increases Uptake [66]
Sister chromatid cohesion protein DCC1 (DSCC1) OTPUVLZT DCC1_HUMAN Affects Response To Substance [68]
------------------------------------------------------------------------------------
⏷ Show the Full List of 93 DOT(s)
Indication(s) of Colchicine
Disease Entry ICD 11 Status REF
Acute gout flare FA25.0 Approved [6]
Acute gouty arthritis FA25.0 Approved [7]
Gout FA25 Approved [8]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [9]
Familial Mediterranean fever N.A. Investigative [8]
Colchicine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Binder [70]
------------------------------------------------------------------------------------
Colchicine Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [71]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [72]
------------------------------------------------------------------------------------
Colchicine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [73]
------------------------------------------------------------------------------------
Colchicine Interacts with 117 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [74]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [75]
Succinate dehydrogenase assembly factor 1, mitochondrial (SDHAF1) OTDG5VW7 SDHF1_HUMAN Decreases Expression [69]
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Decreases Expression [69]
E3 ubiquitin-protein ligase TRIM38 (TRIM38) OT6SP1M9 TRI38_HUMAN Decreases Expression [69]
Torsin-1A (TOR1A) OTYCLGJU TOR1A_HUMAN Decreases Expression [69]
Ectoderm-neural cortex protein 1 (ENC1) OTJEUB6U ENC1_HUMAN Decreases Expression [69]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Decreases Expression [69]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) OT9RDS3H IKKB_HUMAN Increases Phosphorylation [76]
Plexin-B2 (PLXNB2) OT56I2VD PLXB2_HUMAN Decreases Expression [69]
Protein phosphatase 1D (PPM1D) OT8NLZ9D PPM1D_HUMAN Decreases Expression [69]
Regulator of G-protein signaling 16 (RGS16) OTBKZASI RGS16_HUMAN Decreases Expression [69]
E3 ubiquitin-protein ligase RNF113A (RNF113A) OTR6N7HU R113A_HUMAN Decreases Expression [69]
DNA repair protein RAD51 homolog 3 (RAD51C) OTUD6SY5 RA51C_HUMAN Decreases Expression [69]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1) OTEAUJXN TRIA1_HUMAN Decreases Expression [69]
Dual specificity protein phosphatase 14 (DUSP14) OTGODFCR DUS14_HUMAN Decreases Expression [69]
Kinesin-like protein KIF20A (KIF20A) OTXOQHE0 KI20A_HUMAN Decreases Expression [69]
CUGBP Elav-like family member 2 (CELF2) OTLJJ4VT CELF2_HUMAN Increases Expression [77]
G1/S-specific cyclin-E2 (CCNE2) OTBBUKQQ CCNE2_HUMAN Decreases Expression [69]
Prothrombin (F2) OTNFSM49 THRB_HUMAN Affects Activity [78]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [79]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [80]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Expression [78]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases Activity [81]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [82]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Decreases Expression [83]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [84]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [80]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [85]
Microtubule-associated protein tau (MAPT) OTMTP2Z7 TAU_HUMAN Decreases Expression [86]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [87]
Microtubule-associated protein 2 (MAP2) OT6UYT3X MTAP2_HUMAN Decreases Expression [88]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Affects Activity [89]
CD59 glycoprotein (CD59) OTSUMQDH CD59_HUMAN Increases Mutagenesis [90]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Expression [91]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Expression [84]
Tyrosine aminotransferase (TAT) OT2CJ91O ATTY_HUMAN Decreases Expression [92]
Syndecan-1 (SDC1) OTWKRVZC SDC1_HUMAN Decreases Expression [69]
Lactoperoxidase (LPO) OTJ9QKX9 PERL_HUMAN Decreases Expression [88]
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Increases Activity [93]
NADPH:adrenodoxin oxidoreductase, mitochondrial (FDXR) OTPDCK1F ADRO_HUMAN Decreases Expression [69]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Decreases Expression [69]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Phosphorylation [76]
M-phase inducer phosphatase 1 (CDC25A) OTSLKKCO MPIP1_HUMAN Decreases Expression [69]
GTP cyclohydrolase 1 (GCH1) OTOZ6NSL GCH1_HUMAN Decreases Expression [69]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Decreases Expression [88]
Replication factor C subunit 1 (RFC1) OT3L5PK3 RFC1_HUMAN Decreases Expression [69]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [87]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Decreases Activity [94]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [69]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Decreases Expression [69]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Expression [88]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [85]
RNA-binding protein 34 (RBM34) OTX3LUGI RBM34_HUMAN Decreases Expression [69]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Phosphorylation [82]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Increases Phosphorylation [82]
LIM/homeobox protein Lhx2 (LHX2) OTK61NP8 LHX2_HUMAN Decreases Expression [69]
DNA mismatch repair protein Msh6 (MSH6) OT46FP09 MSH6_HUMAN Decreases Expression [69]
RecQ-like DNA helicase BLM (BLM) OTEJOAJX BLM_HUMAN Decreases Expression [69]
Ataxin-1 (ATXN1) OTQF0HNR ATX1_HUMAN Decreases Expression [69]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [85]
Interleukin-2 (IL2) OTGI4NSA IL2_HUMAN Decreases Expression [79]
Ras-related protein Rap-2b (RAP2B) OTD2NDQP RAP2B_HUMAN Decreases Expression [69]
Protein BTG1 (BTG1) OTVJ2CDM BTG1_HUMAN Decreases Expression [69]
Protein BTG2 (BTG2) OTZF6K1H BTG2_HUMAN Decreases Expression [69]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [69]
Myelin transcription factor 1 (MYT1) OTC3660I MYT1_HUMAN Increases Phosphorylation [94]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Decreases Expression [69]
Glutamate receptor ionotropic, NMDA 1 (GRIN1) OTZ5YBO8 NMDZ1_HUMAN Decreases Expression [88]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [85]
Tripartite motif-containing protein 26 (TRIM26) OTS0DJIP TRI26_HUMAN Decreases Expression [69]
E3 ubiquitin-protein ligase TRIM32 (TRIM32) OTJOV0PG TRI32_HUMAN Decreases Expression [69]
Chromatin assembly factor 1 subunit A (CHAF1A) OTXSSY4H CAF1A_HUMAN Decreases Expression [69]
Chromatin assembly factor 1 subunit B (CHAF1B) OTOMK4KH CAF1B_HUMAN Decreases Expression [69]
DNA topoisomerase 3-alpha (TOP3A) OT3CKUI9 TOP3A_HUMAN Decreases Expression [69]
Oligodendrocyte transcription factor 2 (OLIG2) OTMCN6D3 OLIG2_HUMAN Decreases Expression [88]
Protein BTG3 (BTG3) OT9ANHVT BTG3_HUMAN Decreases Expression [69]
Protein-tyrosine kinase 2-beta (PTK2B) OTGAS0I8 FAK2_HUMAN Increases Phosphorylation [77]
Histone RNA hairpin-binding protein (SLBP) OTVYYQRT SLBP_HUMAN Decreases Expression [69]
Nuclear factor of activated T-cells, cytoplasmic 4 (NFATC4) OTTDCUAO NFAC4_HUMAN Decreases Localization [95]
Neutral amino acid transporter B(0) (SLC1A5) OTE2H26Q AAAT_HUMAN Decreases Expression [69]
E3 ubiquitin-protein ligase RNF19B (RNF19B) OTYCWKBP RN19B_HUMAN Decreases Expression [69]
Protein MCM10 homolog (MCM10) OTV0O3JN MCM10_HUMAN Decreases Expression [69]
Partner and localizer of BRCA2 (PALB2) OT6DNDBG PALB2_HUMAN Decreases Expression [69]
E3 ubiquitin-protein ligase TRIM22 (TRIM22) OTJBLG5R TRI22_HUMAN Decreases Expression [69]
Leucine-rich repeat-containing protein 47 (LRRC47) OTSE8NAO LRC47_HUMAN Decreases Expression [69]
Protein tyrosine phosphatase type IVA 1 (PTP4A1) OTK0NFXJ TP4A1_HUMAN Decreases Expression [69]
Cytochrome c oxidase assembly factor 7 (COA7) OTRQJYL6 COA7_HUMAN Decreases Expression [69]
Mitochondrial potassium channel (CCDC51) OTOJNHNA MITOK_HUMAN Decreases Expression [69]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Increases Expression [91]
Integrator complex subunit 15 (INTS15) OT3O4INM INT15_HUMAN Decreases Expression [69]
Pleckstrin homology domain-containing family F member 1 (PLEKHF1) OT9OL16U PKHF1_HUMAN Decreases Expression [69]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Increases Expression [69]
Cell division control protein 6 homolog (CDC6) OTX93FE7 CDC6_HUMAN Decreases Expression [69]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Decreases Expression [69]
Protein orai-3 (ORAI3) OTUP3OH3 ORAI3_HUMAN Decreases Expression [69]
Protein pelota homolog (PELO) OTF3WLIM PELO_HUMAN Decreases Expression [69]
TIMELESS-interacting protein (TIPIN) OT9PZHXV TIPIN_HUMAN Decreases Expression [69]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [96]
tRNA pseudouridine(38/39) synthase (PUS3) OT6WG6M2 PUS3_HUMAN Decreases Expression [69]
Transmembrane protein 185B (TMEM185B) OTGNYS0J T185B_HUMAN Decreases Expression [69]
Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) OT3Q11WQ I20L2_HUMAN Decreases Expression [69]
GrpE protein homolog 1, mitochondrial (GRPEL1) OT8O00YJ GRPE1_HUMAN Decreases Expression [69]
p53-induced death domain-containing protein 1 (PIDD1) OTWFM930 PIDD1_HUMAN Decreases Expression [69]
Fructose-2,6-bisphosphatase TIGAR (TIGAR) OTR7NMRJ TIGAR_HUMAN Decreases Expression [69]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Decreases Expression [69]
Forkhead box protein J2 (FOXJ2) OTPT639J FOXJ2_HUMAN Decreases Expression [69]
Homologous-pairing protein 2 homolog (PSMC3IP) OT9UB5UO HOP2_HUMAN Decreases Expression [69]
Protein CLN8 (CLN8) OT0D4CB5 CLN8_HUMAN Decreases Expression [69]
rRNA methyltransferase 2, mitochondrial (MRM2) OTRYA1HU MRM2_HUMAN Decreases Expression [69]
Frizzled-1 (FZD1) OTZATHVS FZD1_HUMAN Decreases Expression [69]
SH3 and multiple ankyrin repeat domains protein 2 (SHANK2) OTSQTPFQ SHAN2_HUMAN Decreases Expression [88]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Decreases Expression [69]
Pleckstrin homology-like domain family A member 3 (PHLDA3) OTXFUDO2 PHLA3_HUMAN Decreases Expression [69]
Sestrin-1 (SESN1) OTSFDZWL SESN1_HUMAN Decreases Expression [69]
RalA-binding protein 1 (RALBP1) OTBIGB1D RBP1_HUMAN Affects Transport [97]
ATP-binding cassette sub-family A member 13 (ABCA13) OTTHTUQN ABCAD_HUMAN Affects Response To Substance [98]
------------------------------------------------------------------------------------
⏷ Show the Full List of 117 DOT(s)

References

1 ClinicalTrials.gov (NCT05250596) COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)
2 Atorvastatin FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 205945.
5 ClinicalTrials.gov (NCT04380402) Atorvastatin in COVID-19. U.S. National Institutes of Health.
6 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 022351
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7526).
8 Colchicine FDA Label
9 ClinicalTrials.gov (NCT04322565) Colchicine Counteracting Inflammation in COVID-19 Pneumonia. U.S. National Institutes of Health.
10 Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005 Sep-Dec;12(5-6):233-41.
11 Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. 2009 Sep;19(7):481-90. doi: 10.1016/j.numecd.2008.10.003. Epub 2009 Jan 26.
12 Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Inflamm Res. 2012 May;61(5):485-91. doi: 10.1007/s00011-012-0435-9. Epub 2012 Jan 15.
13 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
14 Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042.
15 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
16 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
17 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
18 FDA Drug Development and Drug Interactions
19 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
20 H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
21 Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
24 Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
25 Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
26 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
27 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
28 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
29 Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia. 2005 Aug;60(8):747-53.
30 Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
31 Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
32 [Association of a polymorphic marker Trp719Arg of KIF6 gene with effects of atorvastatin and simvastatin in patients with early ischemic heart disease]. Kardiologiia. 2011;51(9):4-12.
33 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
34 Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism. 2005 Feb;54(2):142-50.
35 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
36 The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006;63(9):738-42.
37 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
38 Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes. Biochem Pharmacol. 2016 Jan 15;100:98-111.
39 Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
40 Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006 Nov;4(11):2397-404. doi: 10.1111/j.1538-7836.2006.02165.x. Epub 2006 Aug 14.
41 Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chem Biol Interact. 2018 May 1;287:32-40. doi: 10.1016/j.cbi.2018.04.005. Epub 2018 Apr 6.
42 Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int J Cardiol. 2011 Feb 3;146(3):319-25. doi: 10.1016/j.ijcard.2009.07.002. Epub 2009 Aug 3.
43 Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem. 2007 Aug 15;101(6):1430-8. doi: 10.1002/jcb.21259.
44 Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels. 2005 Jul;20(4):133-6. doi: 10.1007/s00380-005-0833-9.
45 Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr Nephrol. 2002 Jul;17(7):540-3. doi: 10.1007/s00467-002-0860-z. Epub 2002 May 25.
46 Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway. J Appl Toxicol. 2019 Oct;39(10):1394-1404. doi: 10.1002/jat.3825. Epub 2019 Aug 18.
47 Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010 Oct 1;70(19):7699-709. doi: 10.1158/0008-5472.CAN-10-1626. Epub 2010 Sep 28.
48 Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
49 The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol. 2005 Dec 15;96(12):1699-704. doi: 10.1016/j.amjcard.2005.07.092. Epub 2005 Oct 28.
50 Statins regulate alpha2beta1-integrin expression and collagen I-dependent functions in human vascular smooth muscle cells. J Cardiovasc Pharmacol. 2003 Jan;41(1):89-96. doi: 10.1097/00005344-200301000-00012.
51 Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer. 2008 May 1;122(9):2115-24. doi: 10.1002/ijc.23315.
52 Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Rom J Intern Med. 2007;45(2):193-9.
53 RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006 Nov;13(11):1845-56. doi: 10.1038/sj.cdd.4401873. Epub 2006 Feb 10.
54 Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected]. Eur J Clin Invest. 2003 Jan;33(1):88-91. doi: 10.1046/j.1365-2362.2003.01105.x.
55 Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. Am Heart J. 2006 Jan;151(1):139. doi: 10.1016/j.ahj.2005.10.006.
56 Atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N-methyltransferase level in endothelial cells. J Appl Toxicol. 2021 Jul;41(7):1076-1088. doi: 10.1002/jat.4094. Epub 2020 Oct 19.
57 Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol. 2004 Apr 7;43(7):1188-94. doi: 10.1016/j.jacc.2003.10.046.
58 Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
59 Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. Viruses. 2021 Oct 15;13(10):2084. doi: 10.3390/v13102084.
60 Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
61 Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms. Can J Physiol Pharmacol. 2009 Nov;87(11):915-22. doi: 10.1139/y09-085.
62 Regulation mechanism of ABCA1 expression by statins in hepatocytes. Eur J Pharmacol. 2011 Jul 15;662(1-3):9-14. doi: 10.1016/j.ejphar.2011.04.043. Epub 2011 May 1.
63 Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):175-80. doi: 10.1161/01.ATV.0000104011.88939.06. Epub 2003 Oct 30.
64 Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis. 2011 Dec;16(12):1268-84.
65 Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000 Feb;17(2):209-15. doi: 10.1023/a:1007525616017.
66 The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):244-50. doi: 10.1111/bcpt.12031. Epub 2012 Dec 6.
67 Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22.
68 Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Toxicol Appl Pharmacol. 2022 Oct 1;452:116169. doi: 10.1016/j.taap.2022.116169. Epub 2022 Aug 1.
69 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
70 Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
71 Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53.
72 Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61.
73 Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
74 Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol. 2004 Dec;66(6):1397-405. doi: 10.1124/mol.104.005009. Epub 2004 Sep 1.
75 Functional analysis of MRP1 cloned from bovine. FEBS Lett. 2002 Jun 19;521(1-3):211-3. doi: 10.1016/s0014-5793(02)02816-8.
76 Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem. 2006 Oct;99(2):402-15. doi: 10.1111/j.1471-4159.2006.04005.x.
77 Discovery of a novel compound: insight into mechanisms for acrylamide-induced axonopathy and colchicine-induced apoptotic neuronal cell death. Brain Res. 2001 Aug 3;909(1-2):8-19. doi: 10.1016/s0006-8993(01)02608-7.
78 [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
79 Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4. Am J Gastroenterol. 1992 Apr;87(4):465-70.
80 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
81 Comparative effects of microtubules disruption on glucocorticoid receptor functions in proliferating and quiescent cells. Int J Toxicol. 2010 May-Jun;29(3):326-35. doi: 10.1177/1091581810366486.
82 Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
83 The stability of cytokeratin 18 in human liver cells during colchicine-induced microtubule disruption. Food Chem Toxicol. 2001 Jan;39(1):85-9. doi: 10.1016/s0278-6915(00)00113-7.
84 Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
85 Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
86 Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
87 High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
88 Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
89 Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci. 1999 Aug;112 ( Pt 16):2657-66. doi: 10.1242/jcs.112.16.2657.
90 Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay. Mutat Res. 2006 Dec 1;602(1-2):14-25. doi: 10.1016/j.mrfmmm.2006.07.009. Epub 2006 Oct 11.
91 Synthesis and antitumor evaluation of nitrovinyl biphenyls: anticancer agents based on allocolchicines. ChemMedChem. 2011 May 2;6(5):859-68. doi: 10.1002/cmdc.201100019. Epub 2011 Apr 6.
92 Microtubule disarray in primary cultures of human hepatocytes inhibits transcriptional activity of the glucocorticoid receptor via activation of c-jun N-terminal kinase. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004 Dec;148(2):135-9.
93 Dihydroactinidiolide regulates Nrf2/HO-1 expression and inhibits caspase-3/Bax pathway to protect SH-SY5Y human neuroblastoma cells from oxidative stress induced neuronal apoptosis. Neurotoxicology. 2021 May;84:53-63. doi: 10.1016/j.neuro.2021.02.006. Epub 2021 Feb 20.
94 Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
95 Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT. J Cell Physiol. 2007 Jan;210(1):246-56. doi: 10.1002/jcp.20861.
96 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
97 RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance. Int J Cancer. 2004 Dec 20;112(6):934-42. doi: 10.1002/ijc.20516.
98 Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.